Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in Anticoagulation Management in sub-Saharan Africa.

Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com

This activity is supported by an educational grant from BMSF.

Faculty

1. Prof.  Anne Greist– Hematologist and Medical Oncologist
2. Dr. Gilbert Oburu-Cardiovascular and Thoracic Surgeon
3. Dr. Gilbert Olbara-Pediatrician & Heme/Onc (Fellow)
4. Dr. John Sumba-Hematologist
5. Dr. Mercy Nabwire-Clinical Pharmacist
6. Dr. Hussein Elias– Palliative Care Specialist/Family Medicine
7. Dr. Collins Saina– ICI Oncology Pharmacist
8. Samuel Nyanje-Anticoagulation Pharmaceutical Technologist

This course is accredited by:

Target Audience

The primary target audience for this course comprise the multidisciplinary clinical anticoagulation management team members including, but not limited to medical; fellows; researchers; nurse practitioners and nurses; pharmacists; PharmTechs; clinical officers; physician assistants; Laboratory scientists and technicians and other allied health care professionals.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. Relate how pharmacokinetics and pharmacodynamics principles are used to achieve and maintain anticoagulation control within the patient’s therapy goals.
2. Describe the complexities of managing anticoagulation drug therapy and other treatment modalities.
3. Summarize how pharmaceutical care is applied for patients requiring anticoagulation therapy.
4. Use effective interpersonal skills to better educate patients, caregivers, and other healthcare professionals regarding safe and optimal anticoagulation therapy.
5. Design an anticoagulation management service for effective patient care.
6. Document anticoagulation therapy for patients receiving such therapy.
   Disclosure

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit.

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program

LECTURES

1. Orientation to the course (Chite) Monday 11th May 2020 4:30-5:00 PM EAT
2. Pathophysiology of clotting and the clotting cascade (Olbara) 13th May 2020 4:00-5:30 PM EAT
3. Pharmacology of anticoagulation agents, Pertinent Pharmacokinetic, drug/drug and drug/food interactions with Vit-K antagonists (Anne) 18th May 2020 4:00-5:30 PM EAT
4. Deep Venous Thrombosis: Risk factors, presentation and Treatment (Sumba) 20th May 2020 4:00-5:30 PM EAT
5. Pulmonary Embolism: Risk factors, presentation and Treatment (Hussein) 25th May 2020 4:00-5:30 PM EAT
6. Peri-procedural anticoagulation management: CHEST guidelines and literature review(Oburu) 27th May 2020 4:00-5:30 PM EAT
7. Complications of antithrombotic therapy and management (Sumba) 1st June 2020 4:00-5:30 PM EAT
8. Medication therapy management in anticoagulation clinics (Mercy) 3rd June 2020 4:00-5:30 PM EAT
9. Anticoagulation treatment for atrial fibrillation and valvular heart disorders (Oburu) 8th June 2020 4:00-5:30 PM EAT
10. Communication skills in anticoagulation therapy management (Collins) 10th June 2020 4:00-5:30 PM EAT
11. Developing a patient’s anticoagulation therapy plan (Collins) 15th June 2020 4:00-5:30 PM EAT
12. Monitoring and Evaluation of safety and efficacy parameters in anticoagulation therapy (Anne) 17th June 2020 4:00-5:30 PM EAT
13. Patient education material on anticoagulation therapy (Samuel) 22nd June 2020 4:00-5:30 PM EAT
14. Anticoagulation therapy in pediatric populations (Olbara) 24th June 2020 4:00-5:30 PM EAT
15. Anticoagulation Course Examination (Chite) 29th June 2020 4:00-5:30 PM EAT
16. Discussion of the anticoagulation examination answers (Chite/ Olbara) 1st July 2020 4:005:30 PM EAT

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

All those interested in registration to this course, please send your application  information to info@intercancer.com

Acknowledgements

ICI Acknowledges that the funding for this preceptorship training has been proudly supported by the Bristol-Myers Squibb Foundation (BMSF) Secure the Future Programme.